FOxTROT: Fluoropyrimidine, Oxaliplatin and Targeted Receptor pre-Operative Therapy for colon cancer. A randomised trial assessing whether preoperative chemotherapy and/or an anti-EGFR monoclonal antibody improve outcome in high-risk operable colon cancer.
ACT II: A Second UK Phase III Anal Cancer Trial: A Trial of Chemoradiation and Maintenance Therapy for Patients with Anal Cancer
QUASAR 2: Comparing capecitabine, against capecitabine + Avastin® (bevacizumab) with the expectation that adding bevacizumab to capecitabine may have the potential for improved relapse free and overall survival compared to capecitabine alone.
SCOT: Short Course Oncology Therapy - A study of Adjuvant Chemotherapy in colorectal cancer by the CACTUS & QUASAR 3 Groups
COIN-B: (COIN-Biological) is an open-label, multi-centre, randomised Phase II trial assessing how cetuximab might be best added to chemotherapy, and about the benefits of intermittent chemotherapy in first line treatment of metastatic colorectal cancer.
PICCOLO: A randomised clinical trial of treatment for fluorouracil-resistant advanced colorectal cancer comparing standard single-agent irinotecan (Ir) versus irinotecan plus panitumumab (PAN) and versus irinotecan plus ciclosporin (Cs). The primary endpoints are Ir vs IrCs comparison: Proportion of patients progression-free 12 weeks after randomisation and Ir vs IrPan comparison (patients not previously receiving cetuximab): Overall survival (OS) from randomisation.
EPOC: Peri-operative chemotherapy in patients with resectable colorectal liver metastases - does the addition of an anti-EGF receptor antibody improve progression free survival?
CR07: compares two differentr adiotherapy policies when combined with mesorectal excision. This is a randomised trial to assess whether local recurrence-free rates and quality of life are optimised by giving all patients short course pre-operative radiotherapy, or to give post-operative chemo-radiotherapy only to those at high risk of recurrence.
CHRONICLE: Chemotherapy or no chemotherapy in clear margins after neoadjuvant chemoradiation in locally advanced rectal cancer: A randomised phase III trial of control vs capecitabine plus oxaliplatin.
FOCUS3: This is a study using Ki- Ras and TOPO 1 status to determine subsequent therapy
FACS: A randomised controlled trial to assess the cost-effectiveness of intensive versus no scheduled follow-up in patients who have undergone resection for colorectal cancer with curative intent.
XERXES: Examining the role of Early Neoadjuvant and Synchronous Erbitux in Preoperative Chemo-Radiotherapy using Xeloda followed by Excisional Surgery.
PROSPER:(PROlapse Surgery: PErineal or Rectopexy) The trial is designed to recruit and randomise 1,000 patients, commenced in 2004 and separated short-term perioperative results and functional outcomes by comparing two main abdominal operations, abdominal rectopexy and resection rectopexy, with two principal perineal procedures, the Delorme mucosectomy and the Altemeier perineal rectosigmoidectomy. It will assess basic demography, risk factors, standardised defecatory function and quality of life.
CReST: A UK prospective multicentre randomized trial evaluating the role of endoluminal stenting in the acute management of obstructing colorectal cancer.
FIAT: assessing the use of a collagen fistula plug for fistula in ano.